Arena's obesity drug fails to impress in Phase III
This article was originally published in Scrip
Despite announcing positive top-line data for its lead candidate, lorcaserin, from the first of two pivotal Phase III trials for obesity, Arena Pharmaceuticals' share price fell by 28% to close at $3.23 on Nasdaq as investors labelled the results disappointing.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.